Connecting the dots...
This was big news last year that MANF is potentially an early stage biomarker for ER stress-related kidney diseases. When I saw that I had hoped that somehow the company could get a patent around that or partner with someone that did. I also thought, too bad they just split off their diagnostics as this would fit right in.
Now this week (yesterday) AMBS did a press release on MANF as a potential biomarker for Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome. That wasn't in some little country, but EU and China. Would be the US is next.
Kidney diseases, diabetes, Wolfram's, what's next. You have MANF that is not only potentially help in so many indications, but now can potentially be a valuable diagnostic as well in a number of areas.
MANF: Urine Biomarker for Kidney ER Stress
OCTOBER 7, 2016
Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data
JANUARY 03, 2018
https://www.amarantus.com/news/press-releases...ces-patent
For those that think Avant is just a shell, they are not. There is Theranostics and the OvaDx asset as well. With just Scot and GC on the management team you have to wonder who they are working out the agreements with. Reread the 8K from two weeks ago. Is there a buyout or merger in the works, who know?
https://ir.avantdiagnostics.com/all-sec-filin...load=false
This was big news last year that MANF is potentially an early stage biomarker for ER stress-related kidney diseases. When I saw that I had hoped that somehow the company could get a patent around that or partner with someone that did. I also thought, too bad they just split off their diagnostics as this would fit right in.
Now this week (yesterday) AMBS did a press release on MANF as a potential biomarker for Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome. That wasn't in some little country, but EU and China. Would be the US is next.
Kidney diseases, diabetes, Wolfram's, what's next. You have MANF that is not only potentially help in so many indications, but now can potentially be a valuable diagnostic as well in a number of areas.
MANF: Urine Biomarker for Kidney ER Stress
OCTOBER 7, 2016
Quote:First author Yeawon Kim says, “The discovery of a mechanistic biomarker is a cornerstone for the development of highly targeted treatment in the era of precision medicine .”
The research team is currently validating this biomarker in human kidney diseases associated with ER stress. Urinary MANF has the potential to identify patients at the earliest stages of certain diseases, before a kidney biopsy is even clinically indicated. The biomarker would be invaluable for early diagnosis, prediction of disease progression, and monitoring of treatment response in ER stress-related kidney diseases.
Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data
JANUARY 03, 2018
Quote:MANF Therapeutics, Inc. was issued patents in Europe and China entitled "Beta Cell Disorders" covering the therapeutic and biomarker use of mesencephalic astrocyte-derived neurotrophic factor (MANF) in beta cell disorders, including pre-diabetes, Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome.
https://www.amarantus.com/news/press-releases...ces-patent
For those that think Avant is just a shell, they are not. There is Theranostics and the OvaDx asset as well. With just Scot and GC on the management team you have to wonder who they are working out the agreements with. Reread the 8K from two weeks ago. Is there a buyout or merger in the works, who know?
Quote:Mr. VanderMeer has been brought on to help facilitate the cleanup of the current balance sheet with legacy AP, assist with the Company’s audit, and work towards up listing the company to a national exchange .
https://ir.avantdiagnostics.com/all-sec-filin...load=false
11
